252935-94-7 | 2,6-PYRIDINEDIAMINE, N6-[2-[[4-(2,4-DICHLOROPHENYL)-5-(1H-IMIDAZOL-1-YL)-2-PYRIMIDINYL]AMINO]ETHYL]-3-NITRO-

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$89.00	$62.00
5mg	98%	in stock	$94.00	$66.00
10mg	98%	in stock	$146.00	$102.00
25mg	98%	in stock	$189.00	$132.00
100mg	98%	in stock	$545.00	$381.00
250mg	98%	in stock	$1,032.00	$722.00

Description

• Catalog Number: AF32559
• Chemical Name: 2,6-PYRIDINEDIAMINE, N6-[2-[[4-(2,4-DICHLOROPHENYL)-5-(1H-IMIDAZOL-1-YL)-2-PYRIMIDINYL]AMINO]ETHYL]-3-NITRO-
• CAS Number: 252935-94-7
• Molecular Formula: C20H17Cl2N9O2
• Molecular Weight: 486.3141
• MDL Number: MFCD10565922
• SMILES: Clc1ccc(c(c1)Cl)c1nc(NCCNc2ccc(c(n2)N)[N+](=O)[O-])ncc1n1cncc1

Computed Properties

• Complexity: 645
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 33
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 7
• XLogP3: 4.2

Literature

• Epigenetic changes and disturbed neural development in a human embryonic stem cell-based model relating to the fetal valproate syndrome.

  Human molecular genetics 20120915

• Roles of glycogen synthase kinase 3 in Alzheimer's disease.

  Current Alzheimer research 20120901

• Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20120523

• Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo.

  Diabetes 20030301

• Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes.

  Diabetes 20000201

• Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice.

  Diabetes 19990801

• Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity.

  Proceedings of the National Academy of Sciences of the United States of America 19930815